Metagenomi Therapeutics, Inc. (MGX) stock
MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63+0.00 (+0.13%)
Close on Nov 18, 2026Market cap $23.87MP/E –Yield –
Metagenomi Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Metagenomi Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$85.80M. For fiscal 2025 it was -$89.47M.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$89.47M | – |
| FY2024 | Dec 31, 2024 | -$112.19M | – |
| FY2023 | Dec 31, 2023 | -$101.22M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$19.64M | – |
| Q1 FY2026 | Mar 31, 2026 | -$21.20M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.33M | – |
| Q2 FY2025 | Jun 30, 2025 | -$21.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.13M | – |
| Q4 FY2024 | Dec 31, 2024 | -$26.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$27.84M | – |
| Q2 FY2024 | Jun 30, 2024 | -$26.97M | – |
| Q1 FY2024 | Mar 31, 2024 | -$30.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$22.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$25.99M | – |
| Q2 FY2023 | Jun 30, 2023 | -$29.24M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.66M | – |
See a number that looks wrong?